Tumors that express neuro-developmental markers are of the most highly aggressive subsets of treatment-resistant prostate cancer and have a unique biology that requires novel study and treatment options.

Prostate Cancer Foundation leaders led panel discussions on health and medicine at the Milken Institute’s Global Conference, held from April 27-April 30, 2014, in Beverly Hills, CA. Check out the following full-length videos to learn about lifestyle choices and developing fields of medicine that we think will make some of the biggest impacts in our lives.

This scientific crowdsourcing project, with the Prostate Cancer Foundation as a collaborator, aims to streamline the process of sharing clinical information from many different studies in order to deliver better treatments faster to patients.

Dr. May travels to the Heartland for a major cancer conference, and returns home to Montana with valuable information that enables one of his patients to gain insurance approval for a newly FDA-approved prostate cancer drug.

Each year Castle Connolly Medical Ltd., a research organization based in New York City, publishes their guide, titled “Top Doctors: New York Metro Area.” The guide includes some 6,000 physicians in the region that have been selected by their peers as the crème de la crème of delivery of medical care.

06.27.2013PCF Spotlight

More » The latest on prostate cancer research from PCF and across the web

Tumors that express neuro-developmental markers are of the most highly aggressive subsets of treatment-resistant prostate cancer and have a unique biology that requires novel study and treatment options.

Public Service Announcement will focus on encouraging African-American men to get regularly checked for prostate cancer; the project is a collaborative philanthropic effort between (add)ventures, the Prostate Cancer Foundation and Team Holyfield.